Objective
to report the 5-year clinical outcomes of TAVR using the SAPIEN 3 valve compared to SAVR
Study
multicentre randomised study
Population
patients with aortic stenosis at low surgical risk of <4% (STS-PROM)
Endpoints
composite of all-cause death, stroke, rehospitalisation or heart failure at 5 years
Conclusion
There was no significant difference of the 5-year adverse clinical outcome of treatment of severe symptomatic aortic stenosis patients at low risk between TAVR or SAVR
Mack et al. NEJM 2023 November
